HGEN Humanigen Inc

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

$16.34  -0.66 (-3.86%)
As of 07/23/2021 15:59:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2013
Outstanding shares:  59,083,706
Average volume:  1,395,402
Market cap:   $1,003,832,165
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    444863203
ISIN:        US4448632038
Sedol:      BM9GXF8
Valuation   (See tab for details)
PE ratio:   -9.85
PB ratio:   51.48
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy